Zithromax (azithromycin): FDA Statement on risk of cardiovascular death – Center for Food Safety and Applied Nutrition

In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP. The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new …

Leave a Reply

Your email address will not be published. Required fields are marked *